This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (65)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Surgery, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Perry Shen, MD; Edward A. Levine, MD; Jason Hall, MD; Doug Case, PhD; Greg Russell, MS; Ronald Fleming, PharmD; Richard McQuellon, PhD; Kim R. Geisinger, MD; Brian W. Loggie, MD

Arch Surg. 2003;138:26-33.

Hypothesis  Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Design  Prospective clinical trial.

Setting  Surgical oncology service at a university academic hospital.

Patients  A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997.

Intervention  All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5°C.

Main Outcome Measures  Clinicopathologic factors that independently predicted improved overall survival rates.

Results  Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P = .001), the appendix as a primary site (P = .003), the absence of hepatic parenchymal metastases (P = .01), and complete resection of all gross disease (R1/0 resection) (P<.001). Patients with an R1/0 resection vs an incomplete resection of gross disease (R2 resection) had 3-year overall survival of 68% vs 21% (P<.001).

Conclusions  Patients with peritoneal carcinomatosis have a uniformly poor prognosis. However, in select patients, the natural history of this disease condition may be altered by using the multimodality approach of cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. These results require confirmation in prospective randomized studies.

From Wake Forest University Baptist Medical Center, Departments of General Surgery (Drs Shen, Levine, and Hall), Oncology (Drs Case and McQuellon and Mr Russell), and Pathology (Dr Geisinger), and Kucera Pharmaceutical Co (Dr Fleming), Winston-Salem, NC; and Creighton University Cancer Center, Omaha, Neb (Dr Loggie).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Randomized Trial of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemoperfusion: What It Does and Does Not Tell Us
Levine
Ann. Surg. Oncol. 2008;15:2633-2635.
FULL TEXT  

A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers
Stewart et al.
Ann. Surg. Oncol. 2008;15:2137-2145.
ABSTRACT | FULL TEXT  

Phase I Trial of Pegylated Liposomal Doxorubicin with Hyperthermic Intraperitoneal Chemotherapy in Patients Undergoing Cytoreduction for Advanced Intra-abdominal Malignancy
Harrison et al.
Ann. Surg. Oncol. 2008;15:1407-1413.
ABSTRACT | FULL TEXT  

Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center
Gusani et al.
Ann. Surg. Oncol. 2008;15:754-763.
ABSTRACT | FULL TEXT  

Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis
Lim et al.
Ann. Surg. Oncol. 2007;14:2309-2318.
ABSTRACT | FULL TEXT  

Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy
Yan et al.
Ann. Surg. Oncol. 2007;14:1807-1817.
ABSTRACT | FULL TEXT  

Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma
Yan et al.
JCO 2006;24:4011-4019.
ABSTRACT | FULL TEXT  

Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy
Stewart et al.
Ann. Surg. Oncol. 2006;13:624-634.
ABSTRACT | FULL TEXT  

Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy
Sugarbaker et al.
Ann. Surg. Oncol. 2006;13:635-644.
ABSTRACT | FULL TEXT  

Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions
Stewart et al.
Ann. Surg. Oncol. 2005;12:765-777.
ABSTRACT | FULL TEXT  

Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin
Verwaal et al.
Ann. Surg. Oncol. 2005;12:65-71.
ABSTRACT | FULL TEXT  

Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study
Glehen et al.
JCO 2004;22:3284-3292.
ABSTRACT | FULL TEXT  

Unusual Abdominal Tumors: CASE 1. Pseudomyxoma Peritonei: Response to Capecitabine
Levitz et al.
JCO 2004;22:1518-1520.
FULL TEXT  

Editorial: Problems of Success and Problems of Failure: Recurrent Disease After Cytoreductive Surgery and Intraperitoneal Chemoperfusion
Levine
Ann. Surg. Oncol. 2004;11:351-353.
FULL TEXT  

Recurrences after Peritoneal Carcinomatosis of Colorectal Origin Treated by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and Outcome
Verwaal et al.
Ann. Surg. Oncol. 2004;11:375-379.
ABSTRACT | FULL TEXT  

Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma
Shen et al.
Ann. Surg. Oncol. 2004;11:178-186.
ABSTRACT | FULL TEXT  

Peritoneal Carcinomatosis: What Can We Do About It?
Shen et al.
JCO 2004;22:202-202.
FULL TEXT  

In Reply:
Glehen and Gilly
JCO 2004;22:203-203.
FULL TEXT  

Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis Arising From Gastric Cancer
Glehen et al.
Arch Surg 2004;139:20-26.
ABSTRACT | FULL TEXT  

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
Verwaal et al.
JCO 2003;21:3737-3743.
ABSTRACT | FULL TEXT